Scancell Holdings Plc

Type: Company
Name: Scancell Holdings Plc
First reported Sep 30 2014 - Updated Sep 30 2014 - 1 reports

Scancell Holdings Plc Present at the 14th Annual Biotech in Europe..

TIDMSCLPScancell Holdings Plc30 September 2014 30 September 2014 Scancell Holdings PlcScancell to Present at the 14(th) Annual Biotech in Europe ForumScancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment ... [Published ADVFN UK - Sep 30 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

Oxford Technology : Statement re HMRC Decision

For Immediate Release12th September 2014OXFORD TECHNOLOGY VCT PLCHMRC DecisionShareholders will be aware from an RNS on 13 March 2014 that Oxford Technology VCT Plc ("OT1") had received notice that Her Majesty's Revenue and Customs ("HMRC") had withdrawn ... [Published Investegate - Sep 12 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

Oxford VCTs Tax Status Protected Following Corrective Action

LONDON ( Alliance News ) - Oxford Technology VCT PLC and Oxford Technology 3 VCT PLC Friday said that UK tax authorities have approved of corrective action they had to take in order to protect their tax status.The trusts said the corrective action, which ... [Published 4 Traders - Sep 12 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

Presenting at Upcoming Scientific Conferences

Scancell Holdings PlcScancell to Present at Upcoming Scientific ConferencesScancell Holdings plc, 3rd Annual Cancer Vaccines Conference, London, UK (15-16 September 2014)Phase I/II trial of a novel antibody DNA immunotherapy, SCIB1 ImmunoBody® which targets ... [Published MoneyAM - Sep 12 2014]
First reported Sep 04 2014 - Updated Sep 04 2014 - 4 reports

Scancell Holdings sees annual losses widen

Jessica FinoScancell Holdings, a developer of novel immunotherapies for the treatment of cancer, made an annual loss of £2.22m in the year to 30 April compared to £1.9m last year.The company development spending increased due to additional costs in pre-clinical ... [Published BullBearings - Sep 04 2014]
First reported Aug 27 2014 - Updated Aug 27 2014 - 1 reports

Synergy of SCIB1 with checkpoint inhibitors

Combining SCIB1 with PD-1 blockade enhances tumour destruction and extends survival timesScancell Holdings plc ('Scancell' or the 'Company'), the developer of novel immunotherapies for the treatment of cancer, is pleased to announce new data demonstrating ... [Published Noodls - Aug 27 2014]
First reported Aug 27 2014 - Updated Aug 27 2014 - 1 reports

SCANCELL : DNA ImmunoBody® Patent Granted

Scancell Holdings plc ('Scancell' or the 'Company'), the developer of novel immunotherapies for the treatment of cancer, is pleased to announce that a patent for its DNA ImmunoBody® technology has been granted in the United States.The patent, number 8,742,088, ... [Published 4 Traders - Aug 27 2014]
First reported Aug 12 2014 - Updated Aug 12 2014 - 1 reports

Scancell Holdings Plc: Synergy of SCIB1 With Checkpoint Inhibitors

Combining SCIB1 With PD-1 Blockade Enhances Tumour Destruction and Extends Survival Times ... [Published Marketwire - Breaking News Releases - Aug 12 2014]
First reported Jun 05 2014 - Updated Jun 05 2014 - 1 reports

This week: Clear skies for RapidCloud, Fitbug ups the pace, MediaZest kicks of World Cup

AVCT secures funding award, BGO AGM statement, Blue Inc. intention to float on AIM, BVM contract award, CGNR trenching at Clay Lake, EKF Board appointment and new data, FITB final results, MAGP operations update, MARI first day of dealings, MDZ contract ... [Published Proactiveinvestors United Kingdom RSS feed - Jun 05 2014]

Quotes

Scancell Holdings plc, ( "Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, announces that Dr Richard Goodfellow, Joint CEO of Scancell, is scheduled to present at the 14(th) Annual Biotech in Europe Forum for Global Partnering and Investment held in Basel, Switzerland on Tuesday 30 September 2014."
"Scancell now has two innovative technology platforms in this emerging field, both of which are expected to be of substantial interest to the increasing number of pharmaceutical companies establishing research and development programmes in the area."
"The board remains dedicated to realising value for our shareholders as we continue to build upon the excellent data garnered to date" Goodfellow added
Richard Goodfellow, Joint CEO of Scancell, said: "The cumulative results emerging from our ongoing Phase 1/2 SCIB1 clinical trial, including the destruction of lung metastases in two patients and the apparent prolongation of survival, continues to add to the evidence that SCIB1 has the potential to extend lives without the burden of serious side effects. The rationale for combining SCIB1 and PD-1 blockade, confirmed in recent animal studies, is also compelling."

More Content

All (15) | News (13) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Scancell Holdings Plc Present at the 14th Annua... [Published ADVFN UK - Sep 30 2014]
Oxford VCTs Tax Status Protected Following Corr... [Published 4 Traders - Sep 12 2014]
Oxford Technology : Statement re HMRC Decision [Published Investegate - Sep 12 2014]
Presenting at Upcoming Scientific Conferences [Published MoneyAM - Sep 12 2014]
Scancell Holdings sees annual losses widen [Published BullBearings - Sep 04 2014]
SCANCELL : Full-Year Loss Widens On Development... [Published 4 Traders - Sep 04 2014]
Higher losses at Scancell Holdings [Published Telegraph - Sep 04 2014]
Scancell : Final Results for the year ended 30 ... [Published 4 Traders - Sep 04 2014]
Synergy of SCIB1 with checkpoint inhibitors [Published Noodls - Aug 27 2014]
SCANCELL : DNA ImmunoBody® Patent Granted [Published 4 Traders - Aug 27 2014]
Scancell Holdings Plc: Synergy of SCIB1 With Ch... [Published Marketwire - Breaking News Releases - Aug 12 2014]
This week: Clear skies for RapidCloud, Fitbug u... [Published Proactiveinvestors United Kingdom RSS feed - Jun 05 2014]
Scancell shares rise to 2month high on FDA orph... [Published BioPortfolio - Feb 11 2014]
Scancell shares rise to 2-month high on FDA orp... [Published Proactiveinvestors United Kingdom website - Feb 11 2014]
Scancell Holdings receives Japanese patent for ... [Published PharmaBiz - Dec 16 2013]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Scancell Holdings Plc: Synergy of SCIB1 With Ch... [Published Marketwire - Breaking News Releases - Aug 12 2014]
Combining SCIB1 With PD-1 Blockade Enhances Tumour Destruction and Extends Survival Times ...
Scancell shares rise to 2-month high on FDA orp... [Published Proactiveinvestors United Kingdom website - Feb 11 2014]
Shares in Scancell Holdings ( LON:SCLP ) rose to a two-month high after US Food and Drug Administration granted orphan drug designation (ODD) to the company’s SCIB1 ImmunoBody for the treatment of later-stage cancer. “We believe that the award of ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.